tbuckley/cabot-search huggingface dataset:
Fluoroscopic Guidance for Femoral Artery Access—Pushing Patients Out of the Plane Without a Parachute?
Authors: Alexander C. Fanaroff, Jay Giri
Journal: JAMA Cardiology (2022)

Sanjit S. Jolly, MD, MSc; Sulaiman AlRashidi, MD; Marc-André d'Entremont, MD, MPH; Omar Alansari, MD; Bradley Brochu, MD; Laura Heenan, MSc; Elizabeth Skuriat, MSc; Jessica Tyrwhitt, BSc; Michael Raco, MD; Michael Tsang, MD, MSc; Nicholas Valettas, MD, MASc; James L. Velianou, MD; Tej Sheth, MD; Matthew Sibbald, MD, PhD; Shamir R. Mehta, MD, MSc; Natalia Pinilla-Echeverri, MD, MSc; Jon David Schwalm, MD, MSc; Madhu K. Natarajan, MD, MSc; Andrew Kelly, MD; Elie Akl, MD; Sarah Tawadros, MBBCh; Mercedes Camargo, MD, MASc; Walaa Faidi, MSc; John Bauer, BMRSc; Rachel Moxham, BSc; James Nkurunziza, MD; Gustavo Dutra, MD; Jose Winter, MD
Immunomodulatory hybrid micro-nanofiber scaffolds enhance vascular regeneration
Authors: Siyang Liu, Liying Yao, Yumeng Wang, Yi Li, Yanju Jia, Yueyue Yang, Na Li, Yuanjing Hu, Deling Kong, Xianhao Dong, Kai Wang, Meifeng Zhu
Journal: Bioactive Materials (2022)

The inertness of synthetic polymer materials and the insufficient mechanical strength of reprocessed decellularized extracellular matrix (dECM) limited their promotive efforts on tissue regeneration. Here, we prepared a hybrid scaffold composed of PCL microfibers and human placental extracellular matrix (pECM) nanofibers by co-electrospinning, which was grafted with heparin and further absorbed with IL-4. The hybrid scaffold with improved hemocompatibility firstly switched macrophages to anti-inflammatory phenotype (increased by 18.1%) and then promoted migration, NO production, tube formation of endothelial cells (ECs), and migration and maturation of vascular smooth muscle cells (VSMCs), and ECM deposition
Erratum to ‘Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology’ Medical Image Analysis, Volume 79, July 2022, 102474
Authors: Narmin Ghaffari Laleh, Hannah Sophie Muti, Chiara Maria Lavinia Loeffler, Amelie Echle, Oliver Lester Saldanha, Faisal Mahmood, Ming Y Lu, Christian Trautwein, Rupert Langer, Bastian Dislich, Roman D Buelow, Heike Irmgard Grabsch, Hermann Brenner, Jenny Chang-Claude, Elizabeth Alwers, Titus J Brinker, Firas Khader, Daniel Truhn, Nadine T Gaisa, Peter Boor, Michael Hoffmeister, Volkmar Schulz, Jakob Nikolas Kather
Journal: Medical Image Analysis (2022)
Monkeypox emergence and hosting a safe FIFA World Cup 2022 in Qatar: Challenges and recommendations
Authors: Ramadan Abdelmoez Farahat, Mounir Ould Setti, Amira Yasmine Benmelouka, Iftikhar Ali, Tungki Pratama Umar, Yasmeen Alabdallat, Abdelaziz Abdelaal, Ismail Dergaa
Journal: International Journal of Surgery (2022)
Modern Operative Surgery
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Scalenus Anticus Syndrome and Competitive Swimming
Authors: Saul A. Frankel
Journal: JAMA (1971)

Two cases of scalenus anticus syndrome occurring in competitive free-style swimmers were relieved by scalenotomy and the patients were able to return promptly and successfully to swimming competition. This experience has suggested the mechanism of an apparent causal relationship between freestyle swimming and the scalenus anticus syndrome. In both patients, cessation of competitive swimming resulted in remission of symptoms. Scalenotomy, however, proved to be a simple and effective means of preserving their swimming careers.
Recurrence and Heterogeneity in Painless Thyrotoxic Lymphocytic Thyroiditis
Authors: Harris C. Taylor
Journal: JAMA (1982)

Five patients had recurrent episodes of spontaneously resolving thyrotoxicosis (SRT). Three displayed only the classic low-uptake variety of this disorder, while two had alternating episodes of high-uptake and low-uptake thyrotoxicosis. Two of the three with low uptake only who had thyrotropin displacement activity (TDA) assays had negative results on this test, while one of the patients with alternating high- and low-uptake thyrotoxicosis had a positive TDA assay result, suggesting that the pathogenesis in the two types of SRT may differ. (<i>JAMA</i>1982;248:1085-1088)
Clinical theranostics applications of photo-acoustic imaging as a future prospect for cancer
Authors: Amir Zare, Parisa Shamshiripour, Shahla Lotfi, Mohadeseh Shahin, Vahideh Farzam Rad, Ali-Reza Moradi, Fahimeh Hajiahmadi, Davoud Ahmadvand
Journal: Journal of Controlled Release (2022)
Treatment with THI, an inhibitor of sphingosine-1-phosphate lyase, modulates glycosphingolipid metabolism and results therapeutically effective in experimental models of Huntington’s disease
Authors: Giuseppe Pepe, Luca Capocci, Federico Marracino, Natalia Realini, Paola Lenzi, Katiuscia Martinello, Tiziana Francesca Bovier, Terry Jo Bichell, Pamela Scarselli, Clotilde Di Cicco, Aaron B. Bowman, Filomena A. Digilio, Sergio Fucile, Francesco Fornai, Andrea Armirotti, Rosanna Parlato, Alba Di Pardo, Vittorio Maglione
Journal: Molecular Therapy (2022)
Expression of Receptor Activator of Nuclear Factor-κB Ligand Is Inversely Correlated with Metastatic Phenotype in Breast Carcinoma
Authors: Pardeep Bhatia, M. Melinda Sanders, Marc F. Hansen
Journal: Clinical Cancer Research (2005)

Abstract During normal bone remodeling, the receptor activator of nuclear factor-κB (RANK) interacts with its ligand RANKL, which is present on pre-osteoclasts, resulting in bone resorption and initiation of new bone formation. When breast cancer metastasizes to bone, normal bone remodeling is disturbed by invasion of tumor cells, resulting in osteolytic lesions. We have studied the expression of both RANK and RANKL in 10 nonneoplastic breast samples, 58 infiltrating ductal carcinoma (IDC), and 43 breast cancer bony metastases (BTM). RANK seemed to be present in all samples tested. However, whereas RANKL expression was observed in 90% of nonneoplastic breast, RANKL expression was only observed in 62% of nonmetastatic IDC, 31% of metastatic IDC, and 2% of osteolytic BTM lesions. This decreased or absent expression of RANKL in the tumor cells may allow RANK, which is normally expressed as a receptor on the cell surface, to target RANKL present on the cell surface of normal osteoblasts and stromal cells of the bone. Stimulation of the normal osteoblasts and stromal cells by the tumor cells may then lead to secondary osteoclastogenesis, resulting in the osteolytic phenotype common to breast metastases.
The Vitamine Manual. A Presentation of Essential Data about the New Food Factors.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stage Shift Improves Lung Cancer Survival: Real-World Evidence
Authors: Ching-Yao Yang, Yen-Ting Lin, Li-Ju Lin, Ya-Hsuan Chang, Hsuan-Yu Chen, Yi-Pin Wang, Jin-Yuan Shih, Chong-Jen Yu, Pan-Chyr Yang
Journal: Journal of Thoracic Oncology (2022)

Lung cancer is the global leading cause of cancer death. Taiwan initiated several health policies including smoking cessation, precision therapy, and low-dose computed tomography (LDCT) screening in 1997. We aimed to investigate the effect of public policies on lung cancer survival.We retrieved the nationwide cancer registry from the Ministry of Health and Welfare to evaluate the smoking prevalence and lung cancer incidence and mortality from 1994 to 2020. We also conducted a retrospective analysis of clinical characteristics and survival on 17,298 patients with lung cancer from 2006 to 2019 using the National Taiwan University Hospital database.Taiwan initiated an anti-smoking campaign in 1997, reimbursed tyrosine kinase inhibitors since 2004, and conducted an LDCT screening trial in 2015. Lung cancer incidence keeps rising but the annual percent change in mortality rate gradually decreased from 0.41% to -2.41%. The National Taiwan University Hospital data revealed that the 5-year survival substantially improved from 22.1% in 2006 to 2011 to 54.9% in 2015 to 2020. Improvement was observed in all stages, especially late stages (stage III: from 17.2% to 35.2%; stage IV: from 7.9% to 16.5%). Furthermore, a remarkable shift in cancer stage was observed (stage 0, I, and IIincreased from 19.3% to 62.8%, and stage III and IV decreased from 70.9% to 33.8%). The prominent improvement in survival was primarily driven by the stage shift from advanced to localized, potentially curable disease.This real-world evidence suggested an association between improved survival and LDCT screening and the diagnostic shift from late to early-stage of lung cancer, highlighting the importance of early detection for lung cancer control.
Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection
Authors: Hye Won Jeong, Se-Mi Kim, Min Kyung Jung, Ji Yun Noh, Ji-Seung Yoo, Eun-Ha Kim, Young-Il Kim, Kwangmin Yu, Seung-Gyu Jang, Juryeon Gil, Mark Anthony Casel, Rollon Rare, Jeong Ho Choi, Hee-Sung Kim, Jun Hyoung Kim, Jihye Um, Chaeyoon Kim, Yeonjae Kim, Bum Sik Chin, Sungmin Jung, Jun Yong Choi, Kyoung-Ho Song, Yong-Dae Kim, Jun-Sun Park, Joon Young Song, Eui-Cheol Shin, Young Ki Choi
Journal: Cell Reports Medicine (2022)

Omicron has become the globally dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, creating additional challenges due to its ability to evade neutralization. Here, we report that neutralizing antibodies against Omicron variants are undetected following COVID-19 infection with ancestral or past SARS-CoV-2 variant viruses or after two-dose mRNA vaccination. Compared with two-dose vaccination, a three-dose vaccination course induces broad neutralizing antibody responses with improved durability against different SARS-CoV-2 variants, although neutralizing antibody titers against Omicron remain low. Intriguingly, among individuals with three-dose vaccination, Omicron breakthrough infection substantially augments serum neutralizing activity against a broad spectrum of SARS-CoV-2 variants, including Omicron variants BA.1, BA.2, and BA.5. Additionally, after Omicron breakthrough infection, memory T cells respond to the spike proteins of both ancestral and Omicron SARS-CoV-2 by producing cytokines with polyfunctionality. These results suggest that Omicron breakthrough infection following three-dose mRNA vaccination induces pan-SARS-CoV-2 immunity that may protect against emerging SARS-CoV-2 variants of concern.
Reconsideration of criteria for the Fontan operation. Influence of pulmonary artery size on postoperative hemodynamics of the Fontan operation.
Authors: H Senzaki, T Isoda, A Ishizawa, T Hishi
Journal: Circulation (1994)

BACKGROUND The outcome of the Fontan operation largely depends on patient selection because this procedure is a physiological correction. Among the several selection criteria for the Fontan operation, the importance of adequate size of the pulmonary artery remains controversial. To clarify whether or not pulmonary artery size is indispensable as one of the selection criteria for the Fontan operation, we considered the physiological importance of pulmonary artery size and investigated how pulmonary artery size influenced postoperative hemodynamics of the Fontan operation. METHODS AND RESULTS In congenital heart disease of decreasing pulmonary blood flow, 40 patients were examined for this analysis. Pulmonary artery indexes (cross-sectional area of the right and left pulmonary arteries divided by body surface area) were measured as the expression of pulmonary artery size, and the relations of pulmonary artery index (PAI) to pulmonary vascular resistance (Rp) and compliance (Cp) were studied. There was no significant correlation between PAI and Rp, whereas a significant correlation was found between PAI and Cp (r = .71, P = .001). Furthermore, Cp influenced postoperative hemodynamics of the Fontan operation by affecting peak central venous pressure and total impedance, which was the afterload to the ventricle. Impedance increased abruptly when PAI was less than approximately 100 mm2/m2. CONCLUSIONS The smaller pulmonary artery size is hemodynamically disadvantageous after the Fontan operation, with resultant rise in peak control venous pressure and increased afterload to the single ventricle.
Mode of delivery and survival in babies weighing less than 2000 g at birth.
Journal: BMJ (1981)

not helped by the above measures or for patients in whom the fourth sacral root is menaced.This approach bascd on painstaking attention to applied anatomy, clinical observa- tion, and, in 'the case of epidural local anaesthesia, simple good luck has provided a rational and effective way of dealing with this common problem.This contrasts strongly with the muddle which passes for rational treatment throughout the United Kingdom.The "orthodox" treatments consist of:(1) Useless treatments: heat (and now ultraviolet light), massage, and exercises.Where is the evidence for their effectiveness ?(2) "Correct" treatments done wrongly.Traction given intermittently or only once or twice a week.Manipulation done under anaesthesia-how does the manipulator know he has produced an effective manoeuvre?Epidurals using the wrong local anaesthetic in too small a volume via the wrong route.(3) "Correct" treatments given for the wrong lesion.Traction for hard or irreducible displacements.Manipulation for soft lesions.Epidurals for reducible lesions.Laminectomy for lesions which would respond to con- servative treatment.( 4) Everything (manipulation, traction, epidurals, not forgetting heat and exercises) for all cases of sciatica.
Melanoma differentiation associated gene‐9/syndecan binding protein promotes hepatocellular carcinoma
Authors: Debashri Manna, Saranya Chidambaranathan Reghupaty, Maria Del Carmen Camarena, Rachel G. Mendoza, Mark A. Subler, Jennifer E. Koblinski, Rebecca Martin, Mikhail G. Dozmorov, Nitai D. Mukhopadhyay, Jinze Liu, Xufeng Qu, Swadesh K. Das, Zhao Lai, Jolene J. Windle, Paul B. Fisher, Devanand Sarkar
Journal: Hepatology (2022)

Abstract Background and Aims The oncogene Melanoma differentiation associated gene‐9/syndecan binding protein (MDA‐9/SDCBP) is overexpressed in many cancers, promoting aggressive, metastatic disease. However, the role of MDA‐9 in regulating hepatocellular carcinoma (HCC) has not been well studied. Approach and Results To unravel the function of MDA‐9 in HCC, we generated and characterized a transgenic mouse with hepatocyte‐specific overexpression of MDA‐9 (Alb/MDA‐9). Compared with wild‐type (WT) littermates, Alb/MDA‐9 mice demonstrated significantly higher incidence of N‐nitrosodiethylamine/phenobarbital‐induced HCC, with marked activation and infiltration of macrophages. RNA sequencing (RNA‐seq) in naive WT and Alb/MDA‐9 hepatocytes identified activation of signaling pathways associated with invasion, angiogenesis, and inflammation, especially NF‐κB and integrin‐linked kinase signaling pathways. In nonparenchymal cells purified from naive livers, single‐cell RNA‐seq showed activation of Kupffer cells and macrophages in Alb/MDA‐9 mice versus WT mice. A robust increase in the expression of Secreted phosphoprotein 1 (Spp1/osteopontin) was observed upon overexpression of MDA‐9. Inhibition of NF‐κB pathway blocked MDA‐9–induced Spp1 induction, and knock down of Spp1 resulted in inhibition of MDA‐9–induced macrophage migration, as well as angiogenesis. Conclusions Alb/MDA‐9 is a mouse model with MDA‐9 overexpression in any tissue type. Our findings unravel an HCC‐promoting role of MDA‐9 mediated by NF‐κB and Spp1 and support the rationale of using MDA‐9 inhibitors as a potential treatment for aggressive HCC.
Health Care Personnel Exposures to Subsequently Laboratory-Confirmed Monkeypox Patients — Colorado, 2022
Authors: Kristen E. Marshall, Marlee Barton, Janell Nichols, Marie A. de Perio, David T. Kuhar, Emily Spence-Davizon, Meghan Barnes, Rachel K. Herlihy, Christopher A. Czaja, Theo Abbey, Alyssa Beck, Jennifer Bernal, Tori Burket, Connor Carrillo, Mary Casey, Karen Daily, Catherine Emanuel, Sonakshee Havis, Jillian Jaskunas, Mike Kacka, Ella Keenan, Grace Nelson, Eileen Tran, Leslee Warren, Saher Yunus
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

The risk for monkeypox transmission to health care personnel (HCP) caring for symptomatic patients is thought to be low but has not been thoroughly assessed in the context of the current global outbreak (1). Monkeypox typically spreads through close physical (often skin-to-skin) contact with lesions or scabs, body fluids, or respiratory secretions of a person with an active monkeypox infection. CDC currently recommends that HCP wear a gown, gloves, eye protection, and an N95 (or higher-level) respirator while caring for patients with suspected or confirmed monkeypox to protect themselves from infection† (1,2). The Colorado Department of Public Health and Environment (CDPHE) evaluated HCP exposures and personal protective equipment (PPE) use in health care settings during care of patients who subsequently received a diagnosis of Orthopoxvirus infection (presumptive monkeypox determined by a polymerase chain reaction [PCR] DNA assay) or monkeypox (real-time PCR assay and genetic sequencing performed by CDC). During May 1-July 31, 2022, a total of 313 HCP interacted with patients with subsequently diagnosed monkeypox infections while wearing various combinations of PPE; 23% wore all recommended PPE during their exposures. Twenty-eight percent of exposed HCP were considered to have had high- or intermediate-risk exposures and were therefore eligible to receive postexposure prophylaxis (PEP) with the JYNNEOS vaccine§; among those, 48% (12% of all exposed HCP) received the vaccine. PPE use varied by facility type: HCP in sexually transmitted infection (STI) clinics and community health centers reported the highest adherence to recommended PPE use, and primary and urgent care settings reported the lowest adherence. No HCP developed a monkeypox infection during the 21 days after exposure. These results suggest that the risk for transmission of monkeypox in health care settings is low. Infection prevention training is important in all health care settings, and these findings can guide future updates to PPE recommendations and risk classification in health care settings.
Differential prognostic impact of <scp><i>RUNX1</i></scp> mutations according to frontline therapy in patients with acute myeloid leukemia
Authors: Sangeetha Venugopal, Courtney D. DiNardo, Sanam Loghavi, Wei Qiao, Farhad Ravandi, Marina Konopleva, Tapan Kadia, Kapil Bhalla, Elias Jabbour, Ghayas C. Issa, Walid Macaron, Naval Daver, Gautam Borthakur, Guillermo Montalban‐Bravo, Musa Yilmaz, Keyur P. Patel, Rashmi Kanagal‐Shamanna, Kelly Chien, Abhishek Maiti, Hagop Kantarjian, Nicholas J. Short
Journal: American Journal of Hematology (2022)

RUNX1-mutated (mRUNX1) acute myeloid leukemia (AML) has historically been associated with poor outcomes in the setting of conventional chemotherapy. The prognostic impact of mRUNX1 AML is not well-established in the current era of lower-intensity treatment regimens incorporating venetoclax. We retrospectively analyzed 907 patients with newly diagnosed AML, including 137 patients with mRUNX1 AML, who underwent first-line therapy with intensive chemotherapy (IC), low-intensity therapy without venetoclax (LIT without VEN), or LIT with VEN. When stratified by RUNX1 status, there was no statistically significant difference in outcomes between mRUNX1 and wild-type (wtRUNX1) AML, regardless of therapy received. However, among patients who received LIT with VEN, there was a trend towards superior overall survival (OS) in those with mRUNX1 AML (median OS for mRUNX1 vs. wtRUNX1: 25.1 vs. 11.3 months; 2-year OS 54% vs. 33%; p = 0.12). In patients without another adverse-risk cyto-molecular feature, the presence of mRUNX1 conferred inferior OS in patients who received IC (p = 0.02) or LIT without VEN (p = 0.003) but not in those who received LIT with VEN (mRUNX1 vs. wtRUNX1: 25.1 vs. 30.0 months; 2-year OS 59% vs. 54%; p = 0.86). A multivariate analysis showed possible interaction between RUNX1 mutation status and treatment, suggesting a differential prognostic impact of RUNX1 mutations when patients received IC versus LIT with VEN. In summary, the prognostic impact of mRUNX1 AML may be treatment-dependent, and the presence of RUNX1 mutations may not impact clinical outcomes when venetoclax-based regimens are used.